F-1/A: U-BX Technology Ltd. Files Amendment No. 2 to Form F-1 for Resale of Ordinary Shares and Warrants

U-BX Technology Ltd. has filed an amendment to its Form F-1 registration statement for the resale of up to 14,400,000 ordinary shares, including those issuable upon exercise of warrants, by selling shareholders.

Summary

• U-BX Technology Ltd., a Cayman Islands holding company, has filed Amendment No. 2 to its Form F-1 registration statement with the SEC on February 27, 2025.
• The filing pertains to the resale of up to 14,400,000 ordinary shares by selling shareholders, including up to 13,500,000 shares issuable upon exercise of warrants.
• These ordinary shares and warrants were issued in a private placement completed on November 28, 2024.
• The selling shareholders may offer and sell any, all, or none of the ordinary shares.
• U-BX Technology Ltd. will not receive any proceeds from the sale of these ordinary shares.
• As of February 26, 2025, the last reported closing price of U-BX Technology Ltd.'s ordinary shares on Nasdaq was $2.97.
• The selling shareholders can exercise their warrants to purchase up to 13,500,000 ordinary shares at $0.80 per share, which is a substantial discount to the current market price.
• The company received notification from Nasdaq on October 21, 2024, that it was not in compliance with the minimum bid price requirement.
• A reverse share split at a ratio of one (1)-for-sixteen (16) was implemented to regain compliance, and the company regained compliance on December 13, 2024.
• Investors are cautioned that they are buying shares of a Cayman Islands holding company, not a China-based operating company, which involves unique risks.
• The company conducts its business through PRC subsidiaries, and investors will not have direct ownership in these operating subsidiaries.
• Chinese regulatory authorities could change regulations regarding foreign ownership, which could materially affect the company's operations and the value of its securities.
• The company is required to submit a filing with the CSRC within three business days after the completion of an offering made pursuant to this prospectus and may be subject to the filing requirements under the Overseas Listing Trial Measures for our future offerings and listing of our securities in an overseas market under the Overseas Listing Trial Measures.
• The document discusses risks related to doing business in China, including regulatory uncertainties, data security, and the potential impact of the Holding Foreign Companies Accountable Act.
• The company's management monitors the cash position of each entity and prepares budgets to ensure adequate liquidity.
• The company is an emerging growth company and a foreign private issuer, which allows it to take advantage of reduced reporting requirements.

Sentiment

Score: 5

Explanation: The document is primarily a registration statement, so the sentiment is neutral. It contains both positive aspects (regaining Nasdaq compliance) and negative aspects (risks associated with operating in China, potential share price dilution).

Positives

• The company has regained compliance with Nasdaq's minimum bid price requirement after implementing a reverse share split.
• The company is an emerging growth company and a foreign private issuer, allowing for reduced reporting requirements.

Negatives

• The selling shareholders hold warrants exercisable at a significant discount, which could lead to a decline in the trading price of the ordinary shares.
• The company is subject to regulatory and political risks associated with operating in China.
• The company is required to file with the CSRC within three business days after the completion of an offering made pursuant to this prospectus.
• The company's auditor may be subject to inspection by the PCAOB, which could lead to delisting if the PCAOB is unable to inspect the auditor.

Risks

• The selling shareholders' ability to exercise warrants at a substantial discount could negatively impact the share price.
• Chinese regulatory authorities could change regulations regarding foreign ownership, affecting the company's operations and security values.
• The company may be subject to cybersecurity review by the CAC, potentially requiring delisting from Nasdaq.
• Failure to comply with PRC laws and regulations could lead to penalties and operational disruptions.
• The company's auditor may be subject to inspection by the PCAOB, which could lead to delisting if the PCAOB is unable to inspect the auditor.
• The company is required to file with the CSRC within three business days after the completion of an offering made pursuant to this prospectus.

Future Outlook

The company expects to have a broader reach within the overall insurance industry, as its PRC Operating Entities business focuses on providing insurance technology solutions to insurance carriers interested in applying artificial intelligence technology and online traffic promotion method in their operation. The company believes the future digitization of the insurance industry will create more interest among insurance carriers in using the technology and promotion channels its PRC Operating Entities offers.

Industry Context

The document indicates a shift towards digitization in the insurance industry, with U-BX Technology Ltd. positioning itself as a provider of AI-driven solutions for insurance carriers. This aligns with the broader trend of technology adoption in the financial services sector.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• However, it mentions competitors involved in helping insurance carriers acquire more clients or with insurance carriers policy issuing process, whereas U-BX Technology Ltd. much more rely on internet technology and online traffic promoting.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the potential exercise of warrants.
• Shareholders are subject to risks associated with the company's operations in China.
• The company's ability to pay dividends is dependent on the performance of its PRC subsidiaries and regulatory factors.

Next Steps

• The selling shareholders may offer and sell any, all, or none of the ordinary shares.
• The company may receive proceeds from the exercise of the warrants, which will be used for working capital and general corporate purposes.

Key Dates